Topline data of investigator-initiated study at the University of Minnesota and City of Hope demonstrates 86% overall response rate (OR), including 57% complete response ...

After a median follow-up of 13.3 months (95% CI, 9.04-18.69), the median duration of response was 18.1 months, progression ...

The combination of fruquintinib and serplulimab has shown antitumor activity in treatment-naive advanced non-clear cell renal cell carcinoma.

Overall these findings indicate that adding cabazitaxel to long-term androgen deprivation therapy and radiotherapy did not improve long-term outcomes and increased toxicity in men with high-risk ...

As of Tuesday, February 24, Elicio Therapeutics, Inc.’s ELTX share price has surged by 6.99%, which has investors questioning ...

PEACE-2 finds adding cabazitaxel to ADT plus radiotherapy fails to improve survival in high-risk localized prostate cancer, while increasing severe toxicities and deaths.

The NDA is supported by data from part A of the phase 2 PROSPECT trial, which evaluated tirabrutinib in 48 adult patients with R/R PCNSL.

Maricopa community plans March 14 cancer walk at Maricopa High School to support beloved Pima Butte teacher Denise Palmer during lymphoma treatment.

Researchers sought to determine whether adding nivolumab to R-CHOP would be safe and effective in the previously untreated DLBCL setting.

When he was just 8 years old, Tyler Ralstin spent 10 months in and out of Riley Hospital for Children being treated for acute ...

Results from the phase 2 Daro-PET study (NCT05900973) showed that prostate-specific membrane antigen (PSMA) expression was boosted with short-course darolutamide (Nubeqa) in patients with high-risk ...

Castle Biosciences, Inc. ( CSTL) Q4 2025 Earnings Call February 26, 2026 4:30 PM EST Good afternoon, and welcome to Castle Biosciences Fourth Quarter and Full Year 2025 Conference Call. As a reminder, ...